Rick R. Suarez Appointed U.S. President and Head of the BioPharmaceuticals Business Unit
The appointment strengthens leadership of the company’s U.S. BioPharmaceuticals operations and strategic growth AstraZeneca has named Rick R. Suarez Senior Vice President, US President and Head of the US BioPharmaceuticals…
Candid Therapeutics Plans Phase 2 Autoimmune T-Cell Trials
Phase 2 studies advance following encouraging clinical data for T-cell engagers in autoimmune diseases Candid Therapeutics, Inc. a clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through…
Bayer and Soufflé Therapeutics Partner on Heart-Targeted siRNA
Collaboration focuses on advancing cell-specific siRNA therapies for cardiovascular disease treatment. Bayer and Soufflé Therapeutics™, an innovative biotech company that discovers and develops cell-selective genetic therapies, today announced a strategic…
4Moving Biotech Secures FDA IND Clearance for 4P004, Advancing Disease-Modifying Osteoarthritis Treatment
Regulatory milestone strengthens 4Moving Biotech’s leadership in osteoarthritis drug innovation 4Moving Biotech, a clinical-stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and…
Novo Nordisk’s Wegovy® Oral GLP-1 for Adult Weight Loss Now Widely Available Across the U.S.
Novo Nordisk’s Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America Wegovy® pill is now available, providing those seeking help with their…
Japan Grants Approval for Exdensur (depemokimab) in Severe Asthma and CRSwNP Patients
Japan Approves Exdensur (depemokimab) for Severe Asthma and Nasal Polyps GSK plc has announced that Japan’s Ministry of Health, Labour and Welfare has approved Exdensur (depemokimab) for the treatment of…
Takeda and Protagonist Submit NDA to FDA for Rusfertide in Polycythemia Vera Treatment
Takeda and Protagonist File NDA for Rusfertide in Polycythemia Vera Takeda Pharmaceutical Company Limited and Protagonist Therapeutics, Inc. have announced the submission of a New Drug Application (NDA) to the…
Bayer Secures Breakthrough Therapy Designation in the U.S. and China for Sevabertinib in HER2-Mutant NSCLC
Bayer Regulatory milestones build on FDA’s recent accelerated approval for previously treated HER2-mutant lung cancer patients Bayer announced that regulatory authorities in both the United States and China have granted…
Natera Shares Updated Findings From the ALTAIR Clinical Trial at ASCO GI
Analyses provide deeper insights into outcomes from the ALTAIR study presented at ASCO GI Natera, Inc., a global leader in cell-free DNA and precision medicine, announced that updated analyses from…
Halozyme and Skye Bioscience Enter Global Collaboration to Assess Nimacimab with ENHANZE for Obesity Treatment
Global Licensing Deal Sees Halozyme and Skye Bioscience Partner on Nimacimab-ENHANZE® Obesity Program Halozyme Therapeutics, Inc. and Skye Bioscience, Inc. have disclosed that they entered into a non-exclusive worldwide collaboration…
Orum Therapeutics Names Chad May Chief Scientific Officer
Orum Therapeutics Appoints Chad May as Chief Scientific Officer to Drive Degrader-Antibody Conjugate Innovation and Programs BOSTON & DAEJEON, South Korea a biotechnology company pioneering the field of degrader-antibody conjugates…
Ironwood Pharmaceuticals Confirms FY 2025 Financial Outlook and Provides FY 2026 Financial Projections
Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance BOSTON a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare…